Correlation Between Amicus Therapeutics and Allovir

Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Allovir at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Allovir into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Amicus Therapeutics and Allovir, you can compare the effects of market volatilities on Amicus Therapeutics and Allovir and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Allovir. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Allovir.

Diversification Opportunities for Amicus Therapeutics and Allovir

0.4

Correlation Coefficient

Amicus Therapeutics  Allovir

Very weak diversification

The 3 months correlation between Amicus and Allovir is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Allovir in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allovir and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Allovir. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allovir has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Allovir go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Allovir

Given the investment horizon of 90 days Amicus Therapeutics is expected to under-perform the Allovir. But the stock apears to be less risky and, when comparing its historical volatility, Amicus Therapeutics is 2.38 times less risky than Allovir. The stock trades about -0.07 of its potential returns per unit of risk. The Allovir is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  929.00  in Allovir on December 20, 2024 and sell it today you would earn a total of  52.00  from holding Allovir or generate 5.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.33%
Values	Daily Returns

Amicus Therapeutics  vs.  Allovir

Amicus Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Allovir

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Allovir are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Allovir may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Amicus Therapeutics and Allovir

The main advantage of trading using opposite Amicus Therapeutics and Allovir positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Allovir can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will offset losses from the drop in Allovir's long position.

The idea behind Amicus Therapeutics and Allovir pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.